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Article summary 
 The study is the first to report and analyse data on pregnancy loss following 
prescribing of statins during early pregnancy, work which was possible because the 
GPRD includes medical records for women for the period before as well as during 
pregnancy thus enabling early exposures and losses to be identified. 
 The study found an increased proportion of pregnancies ending in a spontaneous 
loss compared to pregnancies where statins have not been prescribed. 
 The study replicated the results found in other work that has shown that there is no 
difference in the proportion of offspring diagnosed with a major congenital 
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malformation compared with offspring of mothers who have not been exposed to 
statins during pregnancy. 
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Abstract 
Purpose: To determine if there are any differences between the types of pregnancy loss 
experienced by women who have been prescribed a statin just before or early in pregnancy 
compared to those who have not. 
Methods:  A retrospective cohort study using the General Practice Research Database was 
carried out. Women aged between 10-49 years at pregnancy start who received a 
prescription for a statin in the three months before and/or during the first trimester of 
pregnancy were matched to up to ten pregnancies on age at start date, diabetes and 
hypertension status before pregnancy. Pregnancies occurring 1/1/1992-31/3/2009 were 
included. Pregnancy losses were identified and categorised as spontaneous (including 
miscarriage), induced for medical, other or unknown reasons. Freetext was used to 
determine the type of loss where this was not clear from the medical records. 
Results: 281 pregnancies potentially exposed to statins were identified and matched to 
2643 unexposed pregnancies. 54.45% of pregnancies potentially exposed to a statin 
resulted in a delivery compared to 62.81% of those not exposed. 25.27% of all pregnancies 
potentially exposed to a statin resulted in a spontaneous loss compared to 20.81% in those 
not exposed. Using a time to event analysis with exposure as a time dependent covariate 
gave an adjusted hazards ratio of 1.67 (95% CI 1.25 to 2.23) of pregnancy loss in the statin 
exposed group.  
Conclusions: This study is the first to report the differences in types of pregnancy loss 
following the potential exposure to a statin just before or early in pregnancy. 
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Introduction 
There is growing potential for inadvertent use of statins during pregnancy. The increasing 
incidence of type 2 diabetes at a younger age, increasing levels of obesity and increasing 
numbers of women having children later in life lead to greater numbers who may already be 
prescribed statins before conception. A number of studies have investigated major 
congenital malformations and possible associations with statin use during the first 
trimester. Most of the papers published to date have not shown any statistically significant 
increased risk of major malformations following potential exposure to statins during the first 
trimester1-4 although some of these studies were restricted by small sample sizes. However, 
while congenital malformations are very important to consider, pregnancy loss and other 
maternal and child outcomes should also be investigated.  
To date very few studies have investigated pregnancy loss however when evaluating drug 
safety in pregnancy it is vital to consider both deliveries and losses.5, 6 In this paper we will 
address this by evaluating if pregnancy loss due to miscarriage and induced termination are 
different between women who have received prescriptions for statins and those who have 
not.  
Methods 
The General Practice Research Database (GPRD) was used for this study (now known as the 
Clinical Practice Research Datalink). This database contains anonymised primary care 
medical records for approximately 7% of the UK population including prescriptions issued, 
medical diagnoses, test results and maternity information. Pregnancies have been identified 
and matched to offspring using an algorithm where codes relating to pregnancy are 
identified. From these the start and end dates of the pregnancy and outcome are 
determined (for example date of last menstrual period, delivery date). If information is 
missing then a pregnancy that results in a delivery is assumed to last for 40 weeks and a 
pregnancy that results in a termination is assumed to last for ten weeks. More information 
about this algorithm and testing undertaken to verify this is described in earlier work.7  
A cohort of women with pregnancies ending between 1/1/1992 and 31/3/2009 where at 
least one prescription for a statin was recorded in the three months before the start of 
pregnancy or during pregnancy were identified. These pregnancies were matched to up to 
ten pregnancies where a statin was not prescribed. Pregnancies were matched on the 
mother’s age at the start of the pregnancy (+/- 2 years) and whether or not the mother had 
diagnosis codes or treatment for diabetes and/or hypertension before the start of 
pregnancy. For all pregnancies included in the study, females needed to be aged between 
10 and 49 years at the start of pregnancy and have data that is of a standard that is suitable 
for research (UTS) for at least nine months before the start  of pregnancy and throughout 
the pregnancy. We do not expect to identify pregnancies where statins are prescribed in 
those aged 10 years but needed to specify a lower age limit for the study to ensure all those 
eligible are included. 
Pregnancies were matched to babies using month and year of birth corresponding to 
pregnancy end date, general practice number and family number. Babies needed to be 
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registered within 62 days of the pregnancy end date in order to be considered as a match 
for the pregnancy. Major congenital malformations, as defined by EUROCAT 8, were 
identified through medical codes listed in the baby’s medical record and any supporting 
information to confirm the diagnosis, was checked for. Major congenital malformations 
were compared between potentially exposed and unexposed groups. Medical codes relating 
to pregnancy losses were used to determine if the loss was spontaneous, induced for 
medical reasons, induced for non-medical reasons, induced for unknown reasons or where 
the cause could not be identified. From previous work9 we have found that anonymised 
freetext entered by general practitioners to accompany medical codes can aid in 
determining the type of pregnancy loss and in checking details of stillbirths. Freetext was 
reviewed for all pregnancy losses where the type of loss was uncertain and for all stillbirths. 
Any disparities in pregnancy outcomes and dates of pregnancies were updated in the 
dataset used for the analysis. 
Information about the type of statin prescribed and the date of prescription were identified. 
Prescribing was initially categorised according to whether the prescription was issued in the 
three months before pregnancy, trimester 1 (1-90 days from the start of pregnancy), 
trimester 2 (91-180 days from the start of pregnancy) or trimester 3 (from day 181 until the 
end of pregnancy). Information on BMI, smoking and alcohol was identified at or close to 
pregnancy start date and prescribing of other medication for cardiovascular disease, 
diabetes, epilepsy and folic acid during pregnancy were also identified in the year before 
and during pregnancy. Records for pre-eclampsia, gestational diabetes and gestational 
hypertension occurring during pregnancy were also identified. Where data was not 
recorded on smoking status, alcohol use or BMI, this was classified as missing data.  
Statistical analyses were conducted using STATA 13.0. Pregnancy losses were described and 
analysed using the Cox proportional hazards model with left truncation at 8 weeks to 
account for the unknown number of pregnancies where a loss occurs before the pregnancy 
is recognised. This follows previous work 10 and enables us to overcome selection bias that 
would arise from not being able to fully account for all losses in early pregnancy. Failure is 
defined as those pregnancies ending in any type of termination. Potential exposure to a 
statin was defined as a time dependent covariate which used date and length of the 
prescription as the exposure period: only prescriptions overlapping pregnancy weeks 8 to 20 
were included in this analysis. For pregnancy losses, where an exact pregnancy start date 
(such as the date of the last menstrual period) was not recorded, a default pregnancy length 
of ten weeks is used. Given that pregnancy losses are being analysed, this could affect the 
results therefore, where used, default pregnancy lengths of eight weeks and twelve weeks 
were also included to check for any differences in results that may be due to this defaulting. 
Proportionality of hazards was verified and the best model was chosen by evaluating fit with 
each covariate in a univariate model.  
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Results 
In this study, 281 pregnancies were identified where a prescription for a statin had been 
issued in the three months before pregnancy start date (231 pregnancies) and/or during the 
first trimester of pregnancy (124 pregnancies). These pregnancies were matched to 2643 
pregnancies where a statin had not been prescribed during pregnancy or in the three 
months before the pregnancy start date. 262 of the 281 potentially exposed pregnancies 
were matched to at least eight unexposed pregnancies. Of those where matches were more 
difficult to find, twelve of the potentially exposed pregnancies were in women aged 40-49 
years. Characteristics of the study cohort are given in table 1. Those who received a statin 
before or during pregnancy had a higher BMI, were more likely to be a smoker and a greater 
proportion received other prescribed medications, especially those for cardiovascular 
disease. Even though the patients were matched for evidence of a diagnosis of diabetes 
before pregnancy they were not matched on type of diabetes or treatment, hence there 
was a higher number of pregnancies affected by type 2 diabetes that was treated with diet 
in those who did not receive a statin prescription compared to those who did receive a 
statin prescription. 
Table 2 shows the numbers of pregnancies where statins were prescribed in the three 
months before the date of the last menstrual period (LMP) and each trimester. Simvastatin 
and atorvastatin were the statins that were most prescribed during the study period. While 
most women ceased to be prescribed statins after the first trimester, a small number did 
continue to receive prescriptions (8.9%). 
Table 3 summarises the overall pregnancy outcomes identified for this cohort. The 
proportions of deliveries for the cohort is lower than would be expected which is likely to be 
related to the age of the women included in this study and because nearly half had pre-
existing diabetes which increases the risk of miscarriage.9 Where a statin prescription had 
been recorded in the three months before and/or during pregnancy, the proportion of 
pregnancies ending in a delivery was 54.45% compared with 62.81% of pregnancies in those 
where a statin had not been prescribed. For those who had statins prescribed during or in 
the three months before pregnancy, a quarter of all pregnancies ended in a spontaneous 
loss (i.e. miscarriage) and an eighth of all pregnancies ended in a termination induced for 
non-medical reasons (i.e. personal circumstances). To investigate whether these differences 
are due to the numbers of women with diabetes included in the study, separate analyses 
were conducted: 23.29% of pregnancies in women with diabetes and a statin prescription 
experienced a spontaneous loss compared with 20.52% in those who had diabetes but did 
not receive a statin prescription.  
Table 4 shows the results of the univariate analyses comparing delivery with termination for 
all covariates individually. While all three models with differing default time periods for 
pregnancy loss were run, the results of the univariate analysis were very similar especially 
for the default of ten and twelve weeks therefore only one set of results is shown.   
The results indicated that smoking status, prescribing of folic acid and ACE inhibitors should 
be included in the final model. BMI will also be included in the final model as this is an 
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important covariate to consider in this study. While there may be a difference between 
lipophilic and hydrophilic statins, numbers prescribed hydrophilic statins in this study were 
small; it is not possible to include variables for prescription and type of statin in the final 
model due to collinearity problems.  
Table 5 shows the results from the multivariate survival analysis with prescribing of statins 
included as a time dependent covariate. In using this time dependent covariate with left 
truncation at eight weeks, the number of potentially exposed pregnancies that were 
included in this model was 140. Three adjusted models are presented to account for the 
defaulting that is used for pregnancy losses where the pregnancy start date is not known. 
The time periods used were 8, 10 and 12 weeks; the results are very similar therefore the 
default of 10 weeks will be used as the overall result from the study.  
In the unexposed group, 41 major malformations were identified in 40 liveborn infants and 
8 malformations were identified in pregnancies that ended in a termination (2.9% of 
liveborn deliveries and terminations). In the group where a statin was received in the three 
months before or during the first trimester, seven malformations were identified in five 
liveborn infants with no malformations recorded in pregnancies that resulted in a 
termination (3.3% of liveborn deliveries and terminations). 
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Discussion 
This study is one of the first to evaluate differences in pregnancy losses between women 
who are prescribed statins during pregnancy and those who are not. We have reported 
differences in the proportions of deliveries and pregnancy losses between these groups. 
This led to an adjusted hazard ratio of 1.67 (1.25 to 2.23) being found. The main difference 
was in the higher proportion of spontaneous losses: 25.27% of all potentially exposed 
pregnancies compared with 20.81% in those not exposed overall leading to losses occurring 
in 45.55% of all pregnancies in those prescribed a statin compared to 37.20% in those not 
prescribed a statin. Further investigation of the potential association between statin 
prescriptions and a reduced frequency of pregnancies resulting in a delivery indicated that 
smoking and type of diabetes were confounders however effect modification appears to still 
exist. Smoking is a well-known risk factor linked to increased rates of miscarriage and in a 
previous study that we conducted we found higher rates of pregnancy loss in those with 
both type 1 and type 2 diabetes.9 We therefore matched on evidence of diabetes before 
pregnancy to try to overcome some of this difficulty however in the group not prescribed 
statins there were more people who had type 2 diabetes that was managed by diet 
therefore some residual confounding existed.  However, separate analysis of those without 
diabetes indicated that proportions of pregnancies ending in a delivery was lower in those 
prescribed statins (54.11%) than those not prescribed statins (63.21%). We also reported on 
congenital malformations identified in the offspring: these results corresponded with those 
reported by others1-4 with no differences in proportions found between mothers who had 
been prescribed statins and those who had not. 
There are a number of strengths associated with this study. The GPRD is a powerful tool in 
assessing drug safety in pregnancy and has been used to study treatment of many chronic 
diseases during pregnancy.9, 11, 12 Within the GPRD it is possible to include records for 
women from before the start of pregnancy through to the end of pregnancy, to determine 
whether the pregnancy resulted in a delivery or loss and if there were any malformations 
diagnosed, which is not possible with all data sources. The freetext was very valuable in 
determining the type of pregnancy loss where this was not apparent from the medical codes 
recorded. This allowed us to categorise 94% of the pregnancy losses into either spontaneous 
or induced. Other details identified within the freetext included a record noting patient 
concerns about potential exposures and reference was made to the Teratology Information 
Service. The freetext also gave more information about the pregnancy dates than can be 
obtained from just recorded codes. This enhances the accuracy of the study especially with 
regard to determining the classification of exposure. To reduce the potential impact of 
misclassification of statin exposure, a time dependent covariate was defined in order that 
only those prescriptions whose duration included weeks 8 to 20 of pregnancy were used in 
the analysis rather than the initial definition of any prescription in the three months before 
or during the first trimester of pregnancy. Changing the default length of the pregnancy loss 
also gave reassurance that the results are robust even if there has been a small amount of 
misclassification in the dates of the pregnancy. In studies using prescribing records there is 
the possibility of misclassification of exposures whereby a prescription is issued by the 
general practitioner but may not be dispensed or taken. Similarly there may be some 
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misclassification of smoking and alcohol consumption status whereby women make changes 
during pregnancy. 
There are very few other studies that report and evaluate pregnancy loss following exposure 
to statins during early pregnancy. Ofori et al.3 found that 52 of 153 (34%) pregnancies where 
a statin prescription had been filled in the year before or during trimester 1 ended in 
miscarriage, stillbirth or unspecified abortion compared with 27% in those not receiving a 
statin.13 These proportions are lower than those found in our study (stillbirth and pregnancy 
loss 46.3% in statin exposed and 38.2% in the unexposed group). Winterfeld et al. in their 
study using data from the European Network of Teratology Information Services reported 
that 14.5% of pregnancies where a woman had taken a statin during the first trimester of 
pregnancy ended in miscarriage compared with 7.6% of their unexposed comparator 
group.2 These lower proportions potentially reflect lower rates of reporting to the 
Teratology Information Services than data recorded in primary care. A similar study from 
the Canadian Teratology Information Service reported 21.9% of statin exposed pregnancies 
ended in a miscarriage compared with 17.2% in non-exposed pregnancies.4 A study of the 
Merck pharmacovigilance database reported 18 (8%) spontaneous and 49 (21.8%) elective 
abortions of 225 pregnancies with known outcomes although it is likely that these figures 
are underreported.14  
Apart from statins being linked to the differences in pregnancy loss between the groups, a 
potential explanation could be that those who are prescribed statins just before or in the 
early stages of pregnancy have not planned their pregnancy since statins are 
contraindicated in pregnancy. It is generally recognised15 that a break in treatment during 
pregnancy will not have a detrimental effect on a mother’s health. There are very few 
records in the database indicating pre-conception care although these numbers are likely to 
underestimate the true picture. However prescribing of folic acid appears to have a 
protective effect on pregnancy loss which, while underestimated by the database because 
folic acid is available over the counter (400mcg dose) does indicate some pregnancy 
planning in women included in both groups. Other possible medical reasons were also 
investigated for the differences in pregnancy loss including diagnosis of antiphospholipid 
syndrome, systemic lupus erythematosus and polycystic ovary syndrome. Differences in 
proportions between those potentially exposed and those not exposed to statins was very 
small. 
Work in animal models has also the use of statins to treat pre-eclampsia which would 
require statins to be used later on in pregnancy. In our study we found that very few women 
receive statin prescriptions beyond the first trimester of pregnancy: only 34 pregnancies 
where statins were prescribed in the second and/or third trimesters, five of which did not 
receive a prescription during the second trimester and therefore could have been preparing 
for restarting statins following delivery. Just two pregnancies received a prescription for 
pravastatin after the start of the second trimester therefore it is not possible to comment 
on the potential for the treatment of preeclampsia with this medication, from existing 
observational studies.  
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We have shown that there are important differences in the proportions of pregnancies that 
result in a pregnancy loss in those who have been prescribed a statin just before or during 
the first trimester of pregnancy compared with those who have not been prescribed a 
statin. These differences result from a higher proportion of spontaneous losses in those 
potentially exposed to a statin. This is the first study to fully evaluate pregnancy loss with 
statin exposure and emphasises the need to do further research in this area in order to 
further explain or refute this potential association. This is particularly important given the 
number of women of child bearing age who are being prescribed statins but who may also 
want to conceive. 
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Table 1: Characteristics of the study cohort for those who received and did not receive a 
statin prescription including medical conditions diagnosed before pregnancy, medical 
conditions and medications prescribed during pregnancy. 
    Statin prescription 
No statin 
prescription 
   Number % Number % 
Total pregnancies 281  2643   
Total females  266  2453   
Age 15-19 4  40 1.51 
  20-24 20 7.12 198 7.49 
  25-29 44 15.66 405 15.32 
  30-34 64 22.78 616 23.31 
  35-39 73 25.98 767 29.02 
  40-44 63 22.42 529 20.02 
  45-49 13 4.63 88 3.33 
BMI <20 11 3.91 211 7.98 
  20-24 74 26.33 851 32.2 
  25-29 83 29.54 647 24.48 
  30-34 56 19.93 329 12.45 
  35-39 29 10.32 193 7.3 
  40+ 14 4.98 97 3.67 
  Unknown 14 4.98 315 11.92 
Smoking status Smoker 87 30.96 685 25.92 
  Non-smoker 143 50.89 1478 55.92 
  Ex-smoker 50 17.79 451 17.06 
  Unknown 1   29 1.1 
Alcohol status Drinker 173 61.57 1591 60.2 
  Teetotal 62 22.06 444 16.8 
  Ex-drinker 14 4.98 162 6.13 
  Heavy drinker 6 2.14 31 1.17 
  Unknown 26 9.25 415 15.7 
Year of 
pregnancy start  
1992-2000 22 7.83 248 9.38 
2000-04 78 27.76 1130 42.75 
2004-09 181 64.41 1265 47.86 
Conditions diagnosed before pregnancy       
Diabetes  135 48.04 1186 44.87 
  Type 1 48 17.08 364 13.77 
  
Type 2 managed by 
medication 
72 25.62 289 10.93 
  
Type 2 not managed by 
medication 
15 5.34 533 20.17 
Hypertension  47 16.73 366 13.85 
Cardiovascular disease 47 16.73 167 6.32 
Renal disease 13 4.63 29 1.1 
Antiphospholipid syndrome 0  4   
14 
 
Systemic lupus erythematosus 2  4   
Polycystic ovary syndrome 19 6.76 110 4.16 
Conditions diagnosed during pregnancy       
Pre-eclampsia  1 0.36 14 0.53 
Gestational diabetes 7 2.49 15 0.57 
Gestational hypertension 3   13 0.49 
Medications prescribed during pregnancy     
5mg folic acid  50 17.79 283 10.71 
400mcg folic acid* 76 27.05 454 17.18 
Insulin  107 38.08 650 24.59 
Oral antidiabetic treatment 65 23.13 226 8.55 
Treatment for ketoacidosis 34 12.1 295 11.16 
Hypertension medication 25 8.9 109 4.12 
Beta blockers  53 18.86 165 6.24 
Diuretics  38 13.52 139 5.26 
Angina medication 19 6.76 14 0.53 
Arrhythmia medication 3  4   
Non-statin lipid regulating medication 7 2.49 6 0.23 
ACE inhibitors  73 25.98 135 5.11 
Angiotensin II RA 17 6.05 43 1.63 
Calcium channel blockers 32 11.39 106 4.01 
Epilepsy medication 12 4.27 44 1.66 
* Also available over the counter 
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Table 2: Statins prescribed in the three months before pregnancy and during each trimester 
  
3 months 
before LMP 
Trimester 
1 
Trimester 
2 
Trimester 
3 
Total 
pregnancies 
Lipophilic           
Simvastatin 124 98 17 12 152 
Atorvastatin 86 63 9 6 103 
Cerivastatin 2 1 0 0 2 
Hydrophilic      
Rosuvastatin  5 4 0 0 6 
Pravastatin 5 5 1 2 8 
Fluvastatin 4 3 1 0 4 
Combination 5 6 0 0 6 
Total 
pregnancies 231 180 28 20 281 
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Table 3: Pregnancy outcomes for those who receive a prescription for a statin compared 
with those who do not 
Outcomes   
Statin prescription 
  
No statin prescription 
  
N 
 
% of all 
outcomes 
% of 
losses 
N 
 
% of all 
outcomes 
% of 
losses 
Delivery  153 54.45 
 
1660 62.81 
 
 Stillbirth 4 1.42 
 
27 1.02 
 
  Livebirth 149 53.02   1633 61.79   
 
Mother – baby 
matched 
99   1347   
 Multiple births 3   33   
Termination  128 
  
983 
  
 Trimester 1 113 40.21 88.28 866 32.77 88.10 
  Trimester 2 15 5.34 11.72 117 4.43 11.90 
 Spontaneous 71 25.27 55.47 550 20.81 55.95 
 Hydatidiform mole 0 0.00 0.00 4 0.15 0.41 
 Ectopic 3 1.07 2.34 30 1.14 3.05 
 Induced (medical) 1 0.36 0.78 18 0.68 1.83 
 
Induced (non-
medical) 
35 12.46 27.34 269 10.18 27.37 
 
Induced (unknown 
reasons) 
7 2.49 5.47 54 2.04 5.49 
  Unknown 11 3.91 8.59 58 2.19 5.90 
 
  
17 
 
Table 4: Results for the univariate survival models comparing delivery and any type of 
termination with a default of 10 weeks for terminations where the start date of pregnancy 
could not accurately be determined. 
  HR (95% CI) 
Statin exposure 1.77 (1.35 to 2.33) 
Statin type   
No statin Reference 
Lipophilic 1.55 (1.26 to 1.90) 
Hydrophilic 1.19 (0.47 to 3.02) 
Combination 1.23 (0.15 to 10.06) 
Smoker   
Non-smoker Reference 
Yes 1.21 (1.03 to 1.43) 
Ex-smoker 0.96 (0.79 to 1.18) 
Unknown 1.07 (0.48 to 2.37) 
BMI   
<20 1.23 (0.93 to 1.63) 
20-24 Reference 
25-29 1.00 (0.83 to 1.21) 
30-34 1.15 (0.91 to 1.45) 
35-39 1.21 (0.91 to 1.60) 
≥40 1.02 (0.69 to 1.51) 
Unknown 0.87 (0.67 to 1.13) 
Alcohol use   
Non-drinker Reference 
Yes 0.85 (0.71 to 1.03) 
Ex-drinker 0.86 (0.62 to 1.20) 
Heavy drinker 1.23 (0.70 to 2.17) 
Unknown 0.80 (0.62 to 1.04) 
Beta blocker 1.15 (0.87 to 1.51) 
Diuretics 1.09 (0.81 to 1.46) 
Ace inhibitors 1.35 (1.02 to 1.77) 
Angiotensin receptor 
blockers 1.18 (0.76 to 1.84) 
Calcium channel blockers 0.92 (0.65 to 1.30) 
Renal disease 1.71 (0.68 to 4.27) 
Epilepsy 1.05 (0.66 to 1.68) 
Folic acid (high or low 
dose) 0.64 (0.54 to 0.77) 
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Table 5: Multivariate survival analysis using Cox proportional regression with statin 
prescription as a time varying covariate 
 Default 
8 weeks 
HR (95% CI) 
10 weeks 
HR (95% CI) 
12 weeks 
HR (95% CI) 
Potential statin exposure 2.02 (1.26 to 
3.22) 
1.67 (1.25 to 
2.23) 
1.69 (1.23 to 
2.31) 
       
Smoking status      
Non-smoker Reference Reference Reference 
Yes 1.04 (0.80 to 
1.35) 
1.20 (1.02 to 
1.41) 
1.14 (0.96 to 
1.35) 
Ex-smoker 0.94 (0.69 to 
1.29) 
0.95 (0.77 to 
1.16) 
0.94 (0.76 to 
1.16) 
Unknown 0.81 (0.19 to 
3.54) 
1.15 (0.52 to 
2.55) 
1.11 (0.50 to 
2.47) 
       
BMI      
<20 1.14 (0.73 to 
1.77) 
1.17 (0.88 to 
1.55) 
1.18 (0.88 to 
1.57) 
20-24 Reference Reference Reference 
25-29 1.03 (0.76 to 
1.38) 
1.00 (0.82 to 
1.21) 
0.99 (0.82 to 
1.21) 
30-34 1.22 (0.85 to 
1.76) 
1.20 (0.95 to 
1.51) 
1.19 (0.94 to 
1.51) 
35-39 1.28 (0.82 to 
1.99) 
1.24 (0.93 to 
1.65) 
1.19 (0.89 to 
1.60) 
≥40 1.11 (0.61 to 
2.03) 
1.03 (0.69 to 
1.53) 
1.01 (0.68 to 
1.50) 
Unknown 0.89 (0.59 to 
1.35) 
0.86 (0.66 to 
1.12) 
0.87 (0.66 to 
1.14) 
       
Folic acid prescribed (high or 
low dose) 
0.62 (0.47 to 
0.80) 
0.62 (0.52 to 
0.74) 
0.60 (0.50 to 
0.73) 
Ace inhibitor prescribed 1.60 (1.05 to 
2.45) 
1.21 (0.91 to 
1.61) 
1.21 (0.90 to 
1.63) 
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Table 5: update 
  8 weeks 10 weeks 12 weeks 
Statin prescription 1.91 (1.18, 3.11) 1.60 (1.19, 2.15) 1.62 (1.17, 2.24) 
        
Non-smoker Reference Reference Reference 
Smoker 1.05 (0.80, 1.38) 1.21 (1.02, 1.43) 1.15 (0.97, 1.37) 
Ex-smoker 0.97 (0.71, 1.34) 0.98 (0.79, 1.20) 0.98 (0.78, 1.20) 
Unknown 0.80 (0.18, 3.53) 1.16 (0.52, 2.58) 1.13 (0.51, 2.53) 
        
BMI       
<20 1.11 (0.71, 1.74) 1.15 (0.87, 1.53) 1.16 (0.87, 1.55) 
21-24 Reference Reference Reference 
25-29 1.01 (0.75, 1.36) 0.99 (0.82, 1.20) 0.99 (0.81, 1.21) 
30-34 1.21 (0.84, 1.75) 1.20 (0.95, 1.52) 1.20 (0.94, 1.52) 
35-39 1.23 (0.79, 1.93) 1.24 (0.93, 1.65) 1.19 (0.88, 1.59) 
40+ 1.11 (0.60, 2.03) 1.03 (0.69, 1.54) 1.01 (0.68, 1.50) 
Unknown 0.85 (0.54, 1.35) 0.83 (0.62, 1.12) 0.85 (0.63, 1.14) 
        
Teetotaller Reference Reference Reference 
Drinker of alcohol 0.80 (0.60, 1.07) 0.83 (0.69, 1.01) 0.81 (0.66 - 0.98) 
Ex-drinker 1.04 (0.65, 1.67) 0.85 (0.61, 1.19) 0.85 (0.60 - 1.18) 
Heavy drinker 1.12 (0.38, 3.27) 1.11 (0.61, 2.02) 1.18 (0.62 - 2.23) 
Unknown 0.88 (0.57, 1.38) 0.89 (0.67, 1.19) 0.87 (0.65 - 1.15) 
        
Folic acid prescribed (high or low 
dose) 0.59 (0.45, 0.78) 0.61 (0.51, 0.73) 0.60 (0.49, 0.72) 
Ace inhibitor prescribed 1.56 (1.01, 2.42) 1.24 (0.92, 1.66) 1.23 (0.91, 1.67) 
Beta-blocker 1.33 (0.86, 2.07) 1.02 (0.76, 1.37) 1.05 (0.78 - 1.41) 
Diuretics 1.10 (0.70, 1.75) 0.94 (0.69, 1.29) 0.96 (0.70 - 1.32) 
Angiotensin 1.14 (0.54, 2.42) 1.20 (0.76, 1.91) 1.19 (0.75 - 1.90) 
Calcium channel blockers 0.65 (0.37, 1.15) 0.90 (0.63, 1.30) 0.87 (0.60 - 1.26) 
Epilepsy 0.77 (0.34, 1.73) 0.99 (0.61, 1.60) 0.85 (0.50 - 1.42) 
Renal 1.27 (0.32, 4.98) 1.18 (0.46, 3.03) 0.97 (0.35 - 2.66) 
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Table 6 
 
Comparing outcomes of delivery and termination for non-medical reasons 
  8 weeks 10 weeks 12 weeks 
Statin prescription 1.49 (0.62, 3.55) 1.90 (0.97, 3.72) 1.68 (0.82, 3.41) 
        
Smoker       
Yes 1.59 (0.99, 2.55) 1.69 (1.18, 2.44) 1.65 (1.14, 2.38) 
No Reference Reference Reference 
Ex-smoker 0.96 (0.51, 1.81) 0.87 (0.53, 1.43) 0.90 (0.55, 1.49) 
Unknown - 1.26 (0.15, 10.73) 1.12 (0.13, 9.51) 
        
BMI       
<20 0.55 (0.19, 1.53) 0.80 (0.40, 1.58) 0.76 (0.37, 1.54) 
21-24 Reference Reference Reference 
25-29 1.20 (0.69, 2.10) 1.28 (0.83, 1.97) 1.36 (0.87, 2.11) 
30-34 0.92 (0.42, 2.05) 1.17 (0.65, 2.11) 1.14 (0.62, 2.092) 
35-39 1.51 (0.67, 3.41) 1.41 (0.73, 2.71) 1.35 (0.70, 2.59) 
40+ 1.26 (0.41, 3.81) 1.48 (0.66, 3.28) 1.57 (0.70, 3.52) 
Unknown 1.02 (0.48, 2.20) 0.87 (0.46, 1.64) 0.95 (0.50, 1.80) 
        
Folic acid prescribed (high or low 
dose) 0.16 (0.08, 0.32) 0.16 (0.09, 0.28) 0.16 (0.09, 0.28) 
Ace inhibitor prescribed 2.36 (1.00, 5.57) 1.85 (0.91, 3.75) 2.02 (0.99, 4.147) 
        
Alcohol       
Yes 0.82 (0.47, 1.45) 0.77 (0.50, 1.20) 0.75 (0.48 - 1.17) 
No Reference Reference Reference 
Ex-drinker 1.52 (0.59, 3.92) 1.34 (0.64, 2.81) 1.32 (0.63 - 2.718) 
Heavy drinker 2.56 (0.40, 16.44) 1.07 (0.20, 5.70) 1.08 (0.20 - 5.71) 
Unknown 0.87 (0.37, 2.04) 0.91 (0.47, 1.75) 0.83 (0.43 - 1.62) 
        
Beta-blocker 1.37 (0.54, 3.44) 1.16 (0.53, 2.53) 1.21 (0.55 - 2.66) 
Diuretics 1.37 (0.48, 3.91) 1.07 (0.43, 2.64) 1.06 (0.43 - 2.61) 
Angiotensin 0.40 (0.04, 3.89) 0.41 (0.08, 2.16) 0.42 (0.08 - 2.18) 
Calcium channel blockers 0.66 (0.20, 2.16) 0.71 (0.27, 1.88) 0.71 (0.27 - 1.88) 
Epilepsy - 0.52 (0.11, 2.39) 0.24 (0.03 - 1.91) 
Renal - - - 
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Spontaneous loss versus delivery 
 
  8 weeks 10 weeks 12 weeks 
Statin prescription 2.51 (1.27, 4.96) 1.73 (1.17, 2.56) 1.86 (1.21, 2.85) 
        
Smoker       
Yes 0.73 (0.49, 1.07) 1.03 (0.83, 1.28) 1.00 (0.80, 1.26) 
No Reference Reference Reference 
Ex-smoker 1.00 (0.67, 1.50) 0.93 (0.72, 1.20) 0.93 (0.72, 1.21) 
Unknown 0.72 (0.08, 6.30) 1.15 (0.39, 3.35) 1.15 (0.39, 3.36) 
        
BMI       
<20 1.31 (0.71, 2.42) 1.20 (0.82, 1.75) 1.24 (0.84, 1.81) 
21-24 Reference Reference Reference 
25-29 0.88 (0.58, 1.33) 0.89 (0.70, 1.14) 0.88 (0.68, 1.13) 
30-34 1.36 (0.86, 2.16) 1.28 (0.96, 1.69) 1.30 (0.97, 1.73) 
35-39 1.31 (0.72, 2.38) 1.29 (0.91, 1.83) 1.23 (0.85, 1.76) 
40+ 1.09 (0.50, 2.41) 0.94 (0.57, 1.56) 0.91 (0.55, 1.51) 
Unknown 0.74 (0.38, 1.44) 0.81 (0.55, 1.20) 0.83 (0.56, 1.23) 
        
Folic acid prescribed (high or low 
dose) 0.88 (0.63, 1.24) 0.84 (0.68, 1.04) 0.81 (0.65, 1.01) 
Ace inhibitor prescribed 1.02 (0.57, 1.83) 0.98 (0.67, 1.43) 0.90 (0.61, 1.33) 
        
Alcohol       
Yes 0.69 (0.47, 1.00) 0.81 (0.64, 1.03) 0.78 (0.61 - 0.99) 
No Reference Reference Reference 
Ex-drinker 0.78 (0.42, 1.47) 0.66 (0.42, 1.02) 0.67 (0.43 - 1.05) 
Heavy drinker - 1.02 (0.41, 2.53) 1.14 (0.46 - 2.86) 
Unknown 0.85 (0.47, 1.53) 0.82 (0.57, 1.19) 0.80 (0.55 - 1.15) 
        
Beta-blocker 1.62 (0.90, 2.91) 1.10 (0.76, 1.57) 1.15 (0.80 - 1.66) 
Diuretics 1.47 (0.80, 2.71) 1.17 (0.79, 1.71) 1.17 (0.79 - 1.72) 
Angiotensin 0.91 (0.35, 2.37) 1.17 (0.67, 2.02) 
1.23 (0.708 - 
2.16) 
Calcium channel blockers 0.64 (0.31, 1.32 0.94 (0.61, 1.45) 
1.01 (0.567 - 
1.82) 
Epilepsy 1.15 (0.46, 2.86) 1.08 (0.61, 1.91) 1.62 (0.40 - 6.51) 
Renal 
2.05 (0.16, 
26.03) 2.40 (0.66, 8.73) - 
 
 
 
